OSU.EDU


Apply Now

PGY2 Program
ONCOLOGY

Residency Programs

Residency Program Director

  • Tracy Wiczer, PharmD, BCOP

    • PGY2 Oncology Residency Program Director, The James Cancer Hospital at The Ohio State University
    • PGY2 Oncology, The James Cancer Hospital at The Ohio State University
    • PGY1, The Jewish Hospital-Mercy Health, Cincinnati, Ohio
    • PharmD, University of Cinicinnati
    Contact
Previous Year Residents

  • Zachary Arnold, PharmD

    Hematology/Oncology Specialty Practice Pharmacy Float-The James OSUWMC

  • Courtney Krall, PharmD, MPH

    Outpatient Hematology/Oncology Clinical Pharmacy Specialist-The James OSUWMC

  • Nathan Lamb, PharmD, BCPS

    Clinical Pharmacy Specialist-BMT/Cellular Therapy-Moffitt Cancer Center-Tampa, FL

  • Nilmarie Ayala Fontanez, PharmD, MS

    Inpatient/Outpatient Hematology/Oncology Float Specialist-The James OSUWMC

  • Anna Clennon, PharmD

    Clinical Pharmacy Oncology/Hematology Specialist at Froedtert Hospital and the Medical College of Wisconsin

  • Riley Karpen, PharmD, MBA

    Clinical Oncology Pharmacist - The University of Kansas Health System

  • TJ Schieber, PharmD, MBA

    Clinical Oncology Pharmacist - The University of Kansas Health System

  • Jasmine Browning, PharmD

    Hematology/Oncology Clinical Pharmacist, University of Louisville Hospital Brown Cancer Center

  • Tyler Smith, PharmD

    Hematology/Oncology Pharmacist Specialist at The James Cancer Hospital

  • Megan Fleming, PharmD

    Hematology/Oncology Pharmacist Specialist, The James Cancer Hospital

  • Lexus Frazier, PharmD

    Hematology/Oncology Pharmacist Specialist at The James Cancer Hospital

  • Samantha Musson, PharmD

    Hematology/Oncology Pharmacist Specialist at Christ Hospital in Cincinnati, Ohio

  • Shivani Prakshesh Patel, PharmD

    Clinical Pharmacist Specialist, University of Chicago Medicine

  • LeeAnn Geraghty, PharmD

    Clinical Hematology/Oncology Specialist Pharmacist, Norton Healthcare, Louisville, KY

About the PGY2 Oncology Residency Program

Purpose

PGY2 pharmacy residency programs build on Doctor of Pharmacy (PharmD) education and PGY1 pharmacy residency programs to contribute to the development of clinical pharmacists in advanced or specialized practice. PGY2 residencies provide residents with opportunities to function independently as practitioners by conceptualizing and integrating accumulated experience and knowledge incorporating both into the provision of patient care that improves medication therapy. Residents who successfully complete an accredited PGY2 pharmacy residency should possess competencies that qualify them for clinical pharmacist and/or faculty positions and position them to be eligible for attainment of board certification in that practice area (when board certification for the practice area exists).

The purpose of the PGY2 Hematology/Oncology residency is to develop specialized knowledge in the pathophysiology and management of patients with hematology and oncology disorders. This is accomplished through core rotations to strengthen hematology and oncology fundamentals as well as elective rotations with the flexibility to meet the individual’s needs.

The program is designed to develop the resident’s clinical expertise and additionally provide opportunities for teaching, research, and quality improvement. Pharmacists completing the residency will be trained as clinical specialists able to excel as an independent practitioner. The goal of the program is to become an integral member of a Hematology/Oncology multidisciplinary team in a large academic setting.

Residency Sites

The OSUCCC – James strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care — a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of 51 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs sponsored by the NCI. As the cancer program’s 356-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet® designation, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors and more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care.

Read More

The center includes six outpatient chemotherapy infusion clinics, dispensing an estimate of over 75,000 doses of chemotherapy annually. The Department of Pharmacy consists of inpatient and outpatient hematology/oncology clinical specialist pharmacists, pain and palliative medicine pharmacists, anti-coagulation pharmacists, cancer informatics pharmacists, medication assistance pharmacists, and Hematology/Oncology specialty practice pharmacy residents.

The James Cancer Hospital at The Ohio State University offers a one-year postgraduate year two (PGY2) ASHP accredited oncology pharmacy residency program. The clinical pharmacy program is designed to align with our subspecialized disease specific model allowing residents the opportunity to train with clinical specialists who are experts in their subspecialty in both inpatient and ambulatory clinic setting. The program allows residents to develop their hematology/oncology knowledge base including cancer treatment, supportive care, and the role of clinical trials in this patient population. Upon completion of the program, the resident will have the skillset necessary to work as a respected member of a multi-disciplinary hematology/oncology patient care team.

KEY ROTATIONS/EXPERIENCES

The resident will complete a combination of rotations and longitudinal experiences designed around the core objectives specified by ASHP in addition to the resident’s interest.

Orientation: 4 weeks (orientation may be modified for early commit residents)

Research: 3-4 weeks

Hematology

  • Inpatient Acute Leukemia – 4 weeks
  • Bone Marrow Transplantation – 4 weeks
  • Inpatient Lymphoma – 4 weeks
  • Outpatient Hematology Clinics (Chronic Leukemias, Multiple Myeloma, & lymphoma)

Oncology

  • Inpatient Oncology – 4 weeks
  • Outpatient Solid Tumor Clinics
    • Outpatient Breast Cancer – 3 weeks
    • Outpatient Gastrointestinal Cancers (GI) + Melanoma – 4 weeks
    • Outpatient Lung (thoracic)/Gynecology Oncology (Gyn Onc) – 3 weeks
    • Outpatient Genitourinary (GU) – 3 weeks

Clinical trials unit (CTU): 1 week

Pain and Palliative: 2 weeks

Administration: 1 week

  • Required Longitudinal
    • Medication Assistance
    • Medication Safety
    • Teaching
    • Research/MUE

Electives: 4-8 weeks, experiences can be 1-4 weeks in length, electives not listed below can be arranged on specific request

  • Anything in required repeated
  • Inpatient Leukemia/Transplant
  • Inpatient CLL/MM/Misc. Heme
  • Inpatient Benign Heme
  • Inpatient Gynecology
  • Outpatient Leukemia/BMT
  • Outpatient Head & Neck
  • Outpatient Sarcoma
  • Outpatient Melanoma
  • Outpatient Gynecology Oncology
  • Outpatient Neuro-oncology
  • Oncology Administration
  • Informatics
  • Infectious Diseases
  • Pediatric Hematology/Oncology (Nationwide Children’s Hospital)

Key Preceptors

Learn more about the Hematology/Oncology key preceptors:

Read More

INPATIENT/OUTPATIENT HEMATOLOGY
  • Rebecca Evers, PharmD, BCOP
    Outpatient Multiple Myeloma and Lymphoma
  • Pooja Kumar, PharmD, BCOP
    Inpatient/Outpatient BMT and Acute Leukemia
  • Jaelyn Westfield, PharmD, BCOP
    Outpatient Multiple Myeloma and Lymphoma
  • Taylor Gabbard, PharmD, BCOP
    Inpatient Multiple Myeloma
  • Tracelyn Freeman, PharmD, BCOP
    Inpatient/Outpatient BMT and Acute Leukemia
  • Megan Fleming, PharmD, BCOP
    Inpatient/Outpatient BMT and Acute Leukemia
  • Jeremy Sen, PharmD, BCOP
    Inpatient/Outpatient BMT and Acute Leukemia
  • Tyler Everhardt, PharmD, BCOP
    Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma
  • Justin Tossey, PharmD, BCOP
    Inpatient/Outpatient BMT and Acute Leukemia
  • Ally Waller, PharmD, BCOP
    Inpatient/Outpatient BMT and Acute Leukemia
  • Lexus Frazier, PharmD, BCOP
    Inpatient/Outpatient BMT and Acute Leukemia
  • Caitlyn Crawford, PharmD, BCOP
    Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma
  • Lindsay Rosen, PharmD, BCOP
    Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma
  • Jordan Lundberg, PharmD, BCOP
    Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma
  • Tracy Wiczer, PharmD, BCOP
    Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma
INPATIENT/OUTPATIENT ONCOLOGY
  • Matt Arango, PharmD, BCOP
    Outpatient Gastrointestinal Cancer
  • Caleb Good, PharmD
    Inpatient Medical Oncology/Outpatient Melanoma & Neuroendocrine
  • Brianna Archambeau, PharmD, BCOP
    Inpatient Medical Oncology
  • Hunter Patton, PharmD, BCPS
    Inpatient Medical Oncology
  • Molly Russell, PharmD
    Inpatient Medical Oncology/Outpatient Head & Neck Cancer
  • Andrew Stone, PharmD, BCPS
    Inpatient Medical Oncology
  • Michael Berger, PharmD, BCOP
    Outpatient Breast Cancer
  • Stephanie Collins, PharmD, BCOP
    Outpatient Breast Cancer
  • Eric Fela, PharmD, BCOP
    Outpatient Gynecologic Cancers
  • Ambar Khan, PharmD, BCOP
    Outpatient Gynecologic Cancers
  • Megan Hinkley, PharmD, BCOP
    Outpatient Genitourinary Cancers, Lung Cancer
  • Sarah Hoffman, PharmD, BCOP
    Outpatient Sarcoma
  • Gretchen Pardo, PharmD, BCOP
    Inpatient Medical Oncology/Outpatient Head & Neck Cancer
  • Hiba Alzouby, PharmD
    Outpatient Gastrointestinal Oncology
  • Kristen Nymberg, PharmD, BCOP
    Outpatient Genitourinary
  • Tommy Montgomery, PharmD, BCOP
    Inpatient Medical Oncology
  • Allison Reed, PharmD, BCPS, BCOP
    Outpatient Breast Center
  • Lauren Ledbetter, PharmD, BCOP
    Outpatient Lung Cancer
  • Michael Smith, PharmD, BCOP
    Outpatient Lung Cancer & Neuro-oncology
HEMATOLOGY/ONCOLOGY FLOATS
  • Connor Aossey, PharmD
    Hematology/Oncology Float
  • Tyler Dickerson, PharmD, BCOP
    Hematology/Oncology Float
  • Natalia Hartzler, PharmD, BCOP
    Hematology/Oncology Float
  • Tyler Smith, PharmD, BCOP
    Hematology/Oncology Float
HEMATOLOGY/ONCOLOGY ANTICOAGULATION
  • Paige Erdeljac, PharmD, BCACP
    Hematology/Oncology Anticoagulation
  • Stephanie Yager, PharmD, BCACP
    Hematology/Oncology Anticoagulation
PAIN AND PALLIATIVE MEDICINE
  • Jessica Hirsch, PharmD
    Palliative Medicine
  • Gary Houchard, PharmD
    Palliative Medicine
  • Justin Kullgren, PharmD, CPE
    Palliative Medicine
  • Maureen Saphire, PharmD, BCGP, CDP
    Palliative Medicine
OTHER HEMATOLOGY AND ONCOLOGY PRECEPTORS
  • Amber Hartman, PharmD
    Medication Safety
  • Naomi Digiantonio, PharmD, BCPS
    Generalist Pharmacist, Clinical Trials Unit
  • Justin Osorio, PharmD, BCPS
    Generalist Pharmacist, Inpatient Benign Hematology
  • Jacquelyn Williams, PharmD
    Generalist Pharmacist, Inpatient Benign Hematology
ADMINISTRATION
  • Amanda Sabol, PharmD, MS, BCPS
    Assistant Director, Investigational Drug Service
  • Janinah Barreto, PharmD, MS, CPHIMS
    Assistant Director, Pharmacy Informatics Clinical Applications
  • Mitch Dorn, PharmD, MS
    Associate Director, Central Pharmacies
  • Morgan Forshay, PharmD, MS, BCPS
    Pharmacy Manager, Inpatient Oncology
  • Sarah Hudson-Disalle, PharmD
    Pharmacy Manager, Prior Authorization
  • Julie Kennerly-Shah, PharmD, MS, MHA, BCPS
    Associate Director, Cancer Pharmacy Services
  • Ben Lopez, PharmD, MS, MHA, BCPS
    Director, Enterprise Operations
  • Stephen Polley, PharmD, MPA, MS, BCPS
    Assistant Director, Cancer Pharmacy Services
  • Heather Armbruster, PharmD, BCOP
    Pharmacy Manager, Clinical Outpatient Services
  • Emily Dotson, PharmD, BCOP
    Pharmacy Manager, Clinical Inpatient Services

Selected RESIDENT RESEARCH

  • Evaluation of High Dose Methotrexate Clearance, Z. Arnold
  • Comparison of efficacy and infectious complications of haploidentical versus matched unrelated donor allogeneic bone marrow transplants, N. Ayala-Fontanez
  • Impact of Neoadjuvant Therapy on Non-Metastatic Pancreatic Cancer, C. Krall
  • Predicted Fludarabine Exposure Impact on Clinical Outcomes after CAR-T therapy, N. Lamb

Benefits and Additional Requirements

Application Deadline:

January 2

We welcome applications from non-U.S. citizens who have a “green card” (permanent resident status) or a current visa valid through the entire duration of the residency program. The Ohio State University pharmacy residency programs are NOT able to sponsor visas for pharmacy residents (PGY1 or PGY2).

Start Date: July 1

Annual Salary – $56,000

Vacation Days – 10 Days

Staffing Requirement – 19 weekends per year

Completion of a Major Research Project

TEACHING OPPORTUNITIES

Download PDF

Quick Links

Contact Us

A Program Offered By:

College of Pharmacy

Wexner Medical Center

©2025 The Ohio State University Pharmacy Residency Program